Background and Objectives
To evaluate tau PET using 11C-pyridinyl-butadienyl-benzothiazole 3 (11C-PBB3) in the 4-repeat (4R)-tauopathies progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS).
Methods
Retrospective analysis of 11C-PBB3 PET in 2, 7, and 2 patients with CBS, PSP, and Alzheimer dementia (AD), respectively. Normalized 11C-PBB3 uptake in clusters with significant hypometabolism on 18F-FDG-PET and corresponding atlas-based volumes of interest was compared between diagnostic groups.
Results
In accordance with visually appreciable group differences, 11C-PBB3 uptake was significantly higher in dorsolateral frontal and motor cortex in CBS patients and frontal and temporal cortices in AD patients as compared with PSP patients. Patients with PSP showed mildly but significantly higher uptake in midbrain compared with AD patients.
Conclusions
In line with known neuropathological changes, the spatial pattern and magnitude of 11C-PBB3 tau binding differ between CBS, PSP, and AD, which may be of diagnostic utility. Thus, 11C-PBB3 offers a promising lead structure for development of ligands for tau imaging, including 4R-tauopathies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.